Use of multikinase inhibitors/lenvatinib concomitant with radioiodine for the treatment of radioiodine refractory differentiated thyroid cancer
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.5105
Abstract: Thyroid cancer is the most frequent endocrine tumor. However, in locally advanced or metastatic disease we have only two types of treatment at our disposal: radioactive iodine (RAI) when the disease is RAI‐sensitive and multikinase… read more here.
Keywords: radioiodine; multikinase inhibitors; differentiated thyroid; thyroid cancer ... See more keywords
Potential use of multikinase inhibitors in immunosuppressed patients with malignancies including thyroid cancer
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.5106
Abstract: In this article, we focus on a variety of immunosuppression scenarios and whether multikinase inhibitors, as systemic therapy for advanced thyroid carcinoma (TC), could be useful for the treatment of immunocompromised patients with TC. Lenvatinib… read more here.
Keywords: use multikinase; multikinase inhibitors; immunosuppressed patients; potential use ... See more keywords
Use of multikinase inhibitors/lenvatinib in patients with synchronous/metachronous cancers coinciding with radioactive‐resistant differentiated thyroid cancer
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.5107
Abstract: This review focuses on patients with differentiated thyroid carcinoma (DTC) associated with multiple primary malignant neoplasm (MPMN) treated by multikinase inhibitors (MKIs) as systemic treatment for advanced disease. Despite the increasing frequency of MPMNs (many… read more here.
Keywords: use multikinase; multikinase inhibitors; inhibitors lenvatinib; differentiated thyroid ... See more keywords
Treatment outcomes of advanced hepatocellular carcinoma in real‐life practice: Chemotherapy versus multikinase inhibitors
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.5224
Abstract: Multikinase inhibitors (MKIs) represent the main treatment options for advanced hepatocellular carcinoma (aHCC). However, accessibility in developing countries is limited. A chemotherapy, Fluorouracil and Oxaliplatin (FOLFOX), offers a less expensive treatment. Therefore, this study sought… read more here.
Keywords: hepatocellular carcinoma; multikinase inhibitors; real life; advanced hepatocellular ... See more keywords
Predicting HCC Response to Multikinase Inhibitors With In Vivo Cirrhotic Mouse Model for Personalized Therapy
Sign Up to like & getrecommendations! Published in 2020 at "Cellular and Molecular Gastroenterology and Hepatology"
DOI: 10.1016/j.jcmgh.2020.12.009
Abstract: Background & Aims Hepatocellular carcinoma (HCC) arises in a cirrhotic, pro-angiogenic microenvironment. Inhibiting angiogenesis is a key mode of action of multikinase inhibitors and current non-cirrhotic models are unable to predict treatment response. We present… read more here.
Keywords: cirrhotic model; response; multikinase inhibitors; model ... See more keywords
Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy.
Sign Up to like & getrecommendations! Published in 2018 at "Seminars in liver disease"
DOI: 10.1055/s-0038-1673621
Abstract: Multikinase inhibitors with antiangiogenic properties used to be standard therapy for patients with advanced hepatocellular carcinoma (HCC). Recently, several antiangiogenic agents (lenvatinib, cabozantinib, and ramucirumab) have demonstrated antitumor activity for advanced HCC in randomized controlled… read more here.
Keywords: hepatocellular carcinoma; combination; carcinoma; multikinase inhibitors ... See more keywords
PO-008 Anti-tumour properties of novel multikinase inhibitors in sarcomas: synergistic combination with doxorubicin
Sign Up to like & getrecommendations! Published in 2018 at "ESMO Open"
DOI: 10.1136/esmoopen-2018-eacr25.543
Abstract: Introduction Cytotoxic drugs like doxorubicin remain as the most utilised agents in sarcoma treatment. However, advanced sarcomas often show resistance to these drugs, mainly through the overexpression of members of the ATP binding cassette (ABC)… read more here.
Keywords: multikinase inhibitors; drug; effect; anti tumour ... See more keywords
Clinically relevant drug interactions with multikinase inhibitors: a review
Sign Up to like & getrecommendations! Published in 2019 at "Therapeutic Advances in Medical Oncology"
DOI: 10.1177/1758835918818347
Abstract: Multikinase inhibitors (MKIs), including the tyrosine kinase inhibitors (TKIs), have rapidly become an established factor in daily (hemato)-oncology practice. Although the oral route of administration offers improved flexibility and convenience for the patient, challenges arise… read more here.
Keywords: drug interactions; mkis; multikinase inhibitors; drug ... See more keywords
First-line systemic treatment strategies for unresectable hepatocellular carcinoma: A cost-effectiveness analysis
Sign Up to like & getrecommendations! Published in 2022 at "PLOS ONE"
DOI: 10.1371/journal.pone.0279786
Abstract: Abstract: Background Oral multikinase inhibitors and immune checkpoint inhibitors (ICIs) are effective in advanced hepatocellular carcinoma (aHCC) but may increase cost. This study compared the cost-effectiveness of oral multikinase inhibitors and ICIs in first-line patients… read more here.
Keywords: multikinase inhibitors; cost; line; treatment ... See more keywords
Prognostic factors in patients with advanced differentiated thyroid cancer treated with multikinase inhibitors - a single Brazilian center experience.
Sign Up to like & getrecommendations! Published in 2021 at "Archives of endocrinology and metabolism"
DOI: 10.20945/2359-3997000000364
Abstract: Objective The aim of this study was to describe the real-world experience multikinase inhibitors (MKI) in the treatment advanced differentiated thyroid carcinoma (DTC) refractory to radioactive iodine (RAIR) therapy. Methods We reviewed the records of… read more here.
Keywords: advanced differentiated; prognostic factors; multikinase inhibitors; differentiated thyroid ... See more keywords
Chemical Reactivity and Optical and Pharmacokinetics Studies of 14 Multikinase Inhibitors and Their Docking Interactions Toward ACK1 for Precision Oncology
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Chemistry"
DOI: 10.3389/fchem.2022.843642
Abstract: Activated Cdc42-associated kinase 1 (ACK1/TNK2) has a significant role in cell endocytosis, survival, proliferation, and migration. Mutations in ACK1 are closely associated with the occurrence and development of cancers. In this work, a conceptual density… read more here.
Keywords: oncology; inhibitors docking; multikinase inhibitors; chemical reactivity ... See more keywords